FDA Safety Labeling Change Guidance Seeks To Ease Class Confusion
Executive Summary
Final guidance implementing FDAAA authority explains how disagreements between the agency and one or more sponsors could affect the timeline for safety-related labeling changes across a class of products.
You may also be interested in...
Opioid Indication Change Could Draw Legal Challenge From Physicians Group Seeking More Restrictions
FDA tells sponsors to revise the indication for the ER/LA analgesics to highlight appropriate patient selection rather than severity of pain and orders post-marketing studies to identify a dose and duration-of-treatment associated with higher rates of abuse, misuse, addiction, overdose and death.
FDA Labeling Change Rule Is Most Prominent Item On Agency’s To-Do List
HHS’s semi-annual inventory of rulemaking actions under development includes six prescription drug-related rules.
With New Power, New Problems: FDA Confronts Complications of Safety Labeling Change Authority
Drug safety labeling changes that cover large classes of drugs are one of the biggest headaches FDA faces, given its new authority in this area under the Food and Drug Amendments Act, which established a new section 505(o) of the Food, Drug and Cosmetic Act.